TL1A阻断剂目前已经成为一种治疗炎症性和纤维化疾病的潜在新疗法。公开资料显示,多家大型医药公司正在开发这一靶点,比如罗氏(Roche)正在开发的TL1A抗体RVT-3101,已经处于3期临床研究阶段;赛诺菲(Sanofi)于2023年10月宣布与Teva Pharmaceuticals达成一项金额高达约10亿美元的协议,从而开发后者的TL1A靶向疗法TEV’574;辉瑞(Pfizer)TLA1抑制剂PF-06480605早先也已经在治疗溃疡性结肠炎的2期临床研究中取得积极结果。参考资料:[1]中国药物临床试验登记与信息公示平台官网.Retrieved May 9,2024, From https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d
[2] Merck Completes Acquisition of Prometheus Biosciences, Inc. Retrieved June 19, 2023 from https://www.merck.com/news/merck-completes-acquisition-of-prometheus-biosciences-inc/
[3] Acquisition of Prometheus Biosciences. Retrieved April 17, 2023, from https://s21.q4cdn.com/488056881/files/doc_presentations/2023/04/Splash-Investor-Event-Slides-FINAL-1.pdf